Description
Target Validation in Drug Discovery
Coordinators: Metcalf Brian W., Dillon Susan
Language: EnglishSubject for Target Validation in Drug Discovery:
Keywords
transgenic; chemogenomics; inflammation; inhibitors; cancer; antagonists; receptors; glycoprotein
296 p. · 18.2x26 cm · Hardback
Out of Print
Description
/li>Contents
/li>Readership
/li>
I: Pharmaceutical biotechnology for target validation
Chapter 1: GENERATION OF TRANSGENIC ANIMALS
Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS
II: Target validation for biopharmaceutical drug discovery
Chapter 3: CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE
Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES
Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE
Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
III: Validating targets of small molecule approaches
Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS
Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION
Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS
Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST
Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY
INDEX
These books may interest you
Chemical Genomics and Proteomics 220.72 €
Chemical Genomics and Proteomics 85.88 €